|Acquired by||C. R. Bard|
|Convertible Note, 9/2009 ||$100k|
|Seed, 9/2012 ||$15k|
Medafor, Inc. is a medical device company that has developed and commercialized a patented hemostatic agent that has been shown to enhance and accelerate the normal blood clotting process. Medafor’s MPH technology is unparalleled in terms of safety, efficacy, and cost.